{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T02:08:40Z","timestamp":1793758120947,"version":"4.6.1"},"reference-count":109,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"vor","delay-in-days":71,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014895","name":"Southwest Medical University","doi-asserted-by":"publisher","award":["2024PZXNYD03"],"award-info":[{"award-number":["2024PZXNYD03"]}],"id":[{"id":"10.13039\/501100014895","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Research in Microbial Sciences"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.crmicr.2026.100581","type":"journal-article","created":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T16:20:19Z","timestamp":1773505219000},"page":"100581","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Therapeutic challenges and emerging strategies against carbapenem-resistant Acinetobacter baumannii"],"prefix":"10.1016","volume":"10","author":[{"given":"Chunhong","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1190-485X","authenticated-orcid":false,"given":"Zhangyong","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.crmicr.2026.100581_bib0001","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/phar.2366","article-title":"Evaluation of eravacycline: a novel fluorocycline","volume":"40","author":"Alosaimy","year":"2020","journal-title":"Pharmacotherapy"},{"issue":"5","key":"10.1016\/j.crmicr.2026.100581_bib0002","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.00479-22","article-title":"Clinical outcomes of eravacycline in patients treated predominately for carbapenem-resistant Acinetobacter baumannii","volume":"10","author":"Alosaimy","year":"2022","journal-title":"Microbiol. Spectr."},{"issue":"3","key":"10.1016\/j.crmicr.2026.100581_bib0003","doi-asserted-by":"crossref","first-page":"398","DOI":"10.3390\/antibiotics3030398","article-title":"Acquired class D \u03b2-lactamases","volume":"3","author":"Antunes","year":"2014","journal-title":"Antibiotics. (Basel)"},{"issue":"1","key":"10.1016\/j.crmicr.2026.100581_bib0004","doi-asserted-by":"crossref","first-page":"7979","DOI":"10.1038\/s41467-024-52357-8","article-title":"Exploiting human immune repertoire transgenic mice for protective monoclonal antibodies against antimicrobial resistant Acinetobacter baumannii","volume":"15","author":"Baker","year":"2024","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.crmicr.2026.100581_bib0005","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial","volume":"21","author":"Bassetti","year":"2020","journal-title":"Lancet Infect. Dis."},{"issue":"1","key":"10.1016\/j.crmicr.2026.100581_bib0006","doi-asserted-by":"crossref","first-page":"dlae017","DOI":"10.1093\/jacamr\/dlae017","article-title":"Improving phage therapy by evasion of phage resistance mechanisms","volume":"6","author":"Bleriot","year":"2024","journal-title":"JAC Antimicrob. Resist."},{"key":"10.1016\/j.crmicr.2026.100581_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.micpath.2019.03.031","article-title":"Immunogenic reactivity of recombinant PKF and AbOmpA proteins as serum resistance factors against sepsis of Acinetobacter baumannii","volume":"131","author":"Bolourchi","year":"2019","journal-title":"Microb. Pathog."},{"issue":"12","key":"10.1016\/j.crmicr.2026.100581_bib0008","doi-asserted-by":"crossref","first-page":"ofad627","DOI":"10.1093\/ofid\/ofad627","article-title":"Real-life data on cefiderocol efficacy and safety to treat multidrug-resistant Acinetobacter baumannii infections","volume":"10","author":"Campogiani","year":"2023","journal-title":"Open Forum. Infect. Dis."},{"key":"10.1016\/j.crmicr.2026.100581_bib0010","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2021.622704","article-title":"Polymyxin resistance among XDR ST1 carbapenem-resistant Acinetobacter baumannii clone expanding in a teaching hospital","volume":"12","author":"Carrasco","year":"2021","journal-title":"Front. Microbiol."},{"issue":"2","key":"10.1016\/j.crmicr.2026.100581_bib0009","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/1873-3468.12050","article-title":"The outer membrane porin OmpW of Acinetobacter baumannii is involved in iron uptake and colistin binding","volume":"590","author":"Catel-Ferreira","year":"2016","journal-title":"FEBS Lett."},{"key":"10.1016\/j.crmicr.2026.100581_bib0011","doi-asserted-by":"crossref","first-page":"4125","DOI":"10.2147\/IDR.S529016","article-title":"Eravacycline treatment for carbapenem-resistant Acinetobacter baumannii in lung transplant recipients: a real-world retrospective study","volume":"18","author":"Chen","year":"2025","journal-title":"Infect. Drug Resist."},{"issue":"12","key":"10.1016\/j.crmicr.2026.100581_bib0012","doi-asserted-by":"crossref","first-page":"e648","DOI":"10.1016\/S2666-5247(21)00271-8","article-title":"Does cefiderocol heteroresistance explain the discrepancy between the APEKS-NP and CREDIBLE-CR clinical trial results?","volume":"2","author":"Choby","year":"2021","journal-title":"Lancet Microbe"},{"issue":"5","key":"10.1016\/j.crmicr.2026.100581_bib0013","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1473-3099(21)00194-8","article-title":"Widespread cefiderocol heteroresistance in carbapenem-resistant gram-negative pathogens","volume":"21","author":"Choby","year":"2021","journal-title":"Lancet Infect. Dis."},{"issue":"5","key":"10.1016\/j.crmicr.2026.100581_bib0015","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S1473-3099(11)70056-1","article-title":"Metallo-\u03b2-lactamases: a last frontier for \u03b2-lactams?","volume":"11","author":"Cornaglia","year":"2011","journal-title":"Lancet Infect. Dis."},{"issue":"9","key":"10.1016\/j.crmicr.2026.100581_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e30365","article-title":"Adaptive resistance to cefiderocol in carbapenem-resistant Acinetobacter baumannii (CRAB): microbiological and clinical issues","volume":"10","author":"Desmoulin","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.crmicr.2026.100581_bib0017","doi-asserted-by":"crossref","DOI":"10.1038\/nmicrobiol.2017.104","article-title":"ETX2514 is a broad-spectrum \u03b2-lactamase inhibitor for the treatment of drug-resistant gram-negative bacteria including Acinetobacter baumannii","volume":"2","author":"Durand-R\u00e9ville","year":"2017","journal-title":"Nat. Microbiol."},{"issue":"11","key":"10.1016\/j.crmicr.2026.100581_bib0018","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s11274-025-04593-3","article-title":"Antivirulence drugs against Acinetobacter baumannii: where do they stand?","volume":"41","author":"Elanany","year":"2025","journal-title":"World J. Microbiol. Biotechnol."},{"issue":"3","key":"10.1016\/j.crmicr.2026.100581_bib0019","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1128\/AAC.14.3.414","article-title":"CP-45,899, a beta-lactamase inhibitor that extends the antibacterial spectrum of beta-lactams: initial bacteriological characterization","volume":"14","author":"English","year":"1978","journal-title":"Antimicrob. Agents Chemother"},{"issue":"5","key":"10.1016\/j.crmicr.2026.100581_bib0020","doi-asserted-by":"crossref","DOI":"10.1128\/aac.02142-21","article-title":"Cefiderocol- compared to colistin-based regimens for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii","volume":"66","author":"Falcone","year":"2022","journal-title":"Antimicrob. Agents Chemother"},{"issue":"11","key":"10.1016\/j.crmicr.2026.100581_bib0021","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1093\/cid\/ciaa1410","article-title":"Cefiderocol as rescue therapy for Acinetobacter baumannii and other carbapenem-resistant gram-negative infections in intensive care unit patients","volume":"72","author":"Falcone","year":"2021","journal-title":"Clin. Infect. Dis."},{"issue":"Supplement_2","key":"10.1016\/j.crmicr.2026.100581_bib0022","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofad500.1749","article-title":"2126. Safety, tolerability, and pharmacokinetics (PK) in healthy participants following single dose administration of Zosurabalpin, a novel pathogen-specific antibiotic for the treatment of serious Acinetobacter infections","volume":"10","author":"Guenther","year":"2023","journal-title":"Open. Forum. Infect. Dis."},{"key":"10.1016\/j.crmicr.2026.100581_bib0023","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.2147\/IDR.S515207","article-title":"Efficacy and safety of eravacycline combination therapy for carbapenem-resistant Acinetobacter baumannii pneumonia in ICU patients: a retrospective study","volume":"18","author":"Guo","year":"2025","journal-title":"Infect. Drug Resist."},{"issue":"2","key":"10.1016\/j.crmicr.2026.100581_bib0024","doi-asserted-by":"crossref","DOI":"10.1038\/nrmicro.2017.148","article-title":"Uncovering the mechanisms of Acinetobacter baumannii virulence","volume":"16","author":"Harding","year":"2017","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.crmicr.2026.100581_bib0025","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2147\/BTT.S381237","article-title":"Phage therapy: a different approach to fight bacterial infections","volume":"16","author":"Hibstu","year":"2022","journal-title":"Biol. Targets Therapy"},{"issue":"12","key":"10.1016\/j.crmicr.2026.100581_bib0026","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1007\/s40265-024-02102-8","article-title":"The challenge of treating infections caused by metallo-\u03b2-lactamase-producing gram-negative bacteria: a narrative review","volume":"84","author":"Hidalgo-Tenorio","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.crmicr.2026.100581_bib0027","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.3389\/fmicb.2017.02659","article-title":"Phage therapy as a promising new treatment for lung infection caused by carbapenem-resistant Acinetobacter baumannii in mice","volume":"8","author":"Hua","year":"2018","journal-title":"Front. Microbiol."},{"issue":"7","key":"10.1016\/j.crmicr.2026.100581_bib0028","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00290-24","article-title":"Treatment-emergent cefiderocol resistance in carbapenem-resistant Acinetobacter baumannii is associated with insertion sequence ISAba36 in the siderophore receptor pirA","volume":"68","author":"Huang","year":"2024","journal-title":"Antimicrob. Agents Chemother"},{"issue":"3","key":"10.1016\/j.crmicr.2026.100581_bib0029","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01258-23","article-title":"In vitro activity of sulbactam-durlobactam against colistin-resistant and\/or cefiderocol-non-susceptible, carbapenem-resistant Acinetobacter baumannii collected in U.S. hospitals","volume":"68","author":"Iovleva","year":"2024","journal-title":"Antimicrob. Agents Chemother"},{"key":"10.1016\/j.crmicr.2026.100581_bib0030","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1070424","article-title":"Insights into Acinetobacter baumannii protective immunity","volume":"13","author":"Jeffreys","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.crmicr.2026.100581_bib0031","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12866-019-1443-5","article-title":"Efficacy of bacteriophage treatment against carbapenem-resistant Acinetobacter baumannii in Galleria mellonella larvae and a mouse model of acute pneumonia","volume":"19","author":"Jeon","year":"2019","journal-title":"BMC Microbiol."},{"issue":"6","key":"10.1016\/j.crmicr.2026.100581_bib0032","article-title":"Cefiderocol: systematic review of mechanisms of resistance, heteroresistance and In vivo emergence of resistance","volume":"11","author":"Karakonstantis","year":"2022","journal-title":"Antibiotics. (Basel)"},{"issue":"9","key":"10.1016\/j.crmicr.2026.100581_bib0033","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/S1473-3099(23)00184-6","volume":"23","author":"Kaye","year":"2023","journal-title":"Lancet Infect. Dis."},{"issue":"2","key":"10.1016\/j.crmicr.2026.100581_bib0034","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ijantimicag.2018.10.007","volume":"53","author":"Kazmierczak","year":"2018","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"13","key":"10.1016\/j.crmicr.2026.100581_bib0035","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1007\/s40265-023-01920-6","article-title":"Sulbactam\/Durlobactam: first approval","volume":"83","author":"Keam","year":"2023","journal-title":"Drugs"},{"issue":"7","key":"10.1016\/j.crmicr.2026.100581_bib0036","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14071357","article-title":"Safety and prophylactic efficacy of liposome-based vaccine against the drug-resistant Acinetobacter baumannii in mice","volume":"14","author":"Khan","year":"2022","journal-title":"Pharmaceutics."},{"issue":"8","key":"10.1016\/j.crmicr.2026.100581_bib0037","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01063-24","article-title":"Acinetobacter baumannii treatment strategies: a review of therapeutic challenges and considerations","volume":"69","author":"Kubin","year":"2025","journal-title":"Antimicrob. Agents Chemother"},{"issue":"2","key":"10.1016\/j.crmicr.2026.100581_bib0038","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1039\/D4MD00745J","article-title":"Natural peptides and their synthetic congeners acting against Acinetobacter baumannii through the membrane and cell wall: latest progress","volume":"16","author":"Kumar","year":"2024","journal-title":"RSC Med. Chem."},{"issue":"1","key":"10.1016\/j.crmicr.2026.100581_bib0039","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.02351-23","article-title":"Eravacycline, the first four years: health outcomes and tolerability data for 19 hospitals in 5 U.S. regions from 2018 to 2022","volume":"12","author":"Kunz Coyne","year":"2023","journal-title":"Microbiol. Spectr."},{"issue":"3","key":"10.1016\/j.crmicr.2026.100581_bib0040","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens10030373","article-title":"Acinetobacter baumannii antibiotic resistance mechanisms","volume":"10","author":"Kyriakidis","year":"2021","journal-title":"Pathogens"},{"issue":"4","key":"10.1016\/j.crmicr.2026.100581_bib0041","doi-asserted-by":"crossref","first-page":"ofy064","DOI":"10.1093\/ofid\/ofy064","article-title":"Phage therapy for a multidrug-resistant Acinetobacter baumannii craniectomy site infection","volume":"5","author":"LaVergne","year":"2018","journal-title":"Open Forum. Infect. Dis."},{"issue":"10","key":"10.1016\/j.crmicr.2026.100581_bib0042","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1007\/s10096-019-03590-3","article-title":"Eravacycline, a newly approved fluorocycline","volume":"38","author":"Lee","year":"2019","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"issue":"5","key":"10.1016\/j.crmicr.2026.100581_bib0043","doi-asserted-by":"crossref","first-page":"5397","DOI":"10.1007\/s11033-019-04994-2","article-title":"DNA vaccine encoding OmpA and Pal from Acinetobacter baumannii efficiently protects mice against pulmonary infection","volume":"46","author":"Lei","year":"2019","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.crmicr.2026.100581_bib0044","article-title":"Emergence of eravacycline heteroresistance in carbapenem-resistant Acinetobacter baumannii isolates in China","volume":"14","author":"Li","year":"2024","journal-title":"Front. Cell Infect. Microbiol."},{"key":"10.1016\/j.crmicr.2026.100581_bib0045","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jgar.2022.05.020","article-title":"Synergism of eravacycline combined with other antimicrobial agents against carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii","volume":"30","author":"Li","year":"2022","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"10.1016\/j.crmicr.2026.100581_bib0046","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2024.1504013","article-title":"In vitro activities of eravacycline against clinical bacterial isolates: a multicenter study in Guangdong, China","volume":"15","author":"Liao","year":"2024","journal-title":"Front. Microbiol."},{"issue":"4","key":"10.1016\/j.crmicr.2026.100581_bib0047","doi-asserted-by":"crossref","DOI":"10.3390\/toxins15040268","article-title":"Therapeutic prospection of animal venoms-derived antimicrobial peptides against infections by multidrug-resistant Acinetobacter baumannii: a systematic review of pre-clinical studies","volume":"15","author":"Lima","year":"2023","journal-title":"Toxins. (Basel)"},{"issue":"1","key":"10.1016\/j.crmicr.2026.100581_bib0048","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1080\/22221751.2022.2093134","article-title":"Epidemiological and genetic characteristics of clinical carbapenem-resistant Acinetobacter baumannii strains collected countrywide from hospital intensive care units (ICUs) in China","volume":"11","author":"Liu","year":"2022","journal-title":"Emerg. Microbes. Infect."},{"key":"10.1016\/j.crmicr.2026.100581_bib0049","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.3389\/fmicb.2020.01532","article-title":"Antimicrobial peptide Cec4 eradicates the bacteria of clinical carbapenem-resistant Acinetobacter baumannii biofilm","volume":"11","author":"Liu","year":"2020","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.crmicr.2026.100581_bib0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110650","article-title":"Synergistic immunoprotection by Oma87 and Bap against Acinetobacter baumannii sepsis model","volume":"122","author":"Mansouri","year":"2023","journal-title":"Int. Immunopharmacol."},{"issue":"13","key":"10.1016\/j.crmicr.2026.100581_bib0051","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25136814","article-title":"Unveiling the secrets of Acinetobacter baumannii: resistance, current treatments, and future innovations","volume":"25","author":"Marino","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.crmicr.2026.100581_bib0052","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02171-20","article-title":"New perspectives on antimicrobial agents: cefiderocol","volume":"65","author":"McCreary","year":"2021","journal-title":"Antimicrob. Agents Chemother"},{"issue":"4","key":"10.1016\/j.crmicr.2026.100581_bib0053","doi-asserted-by":"crossref","first-page":"ofae140","DOI":"10.1093\/ofid\/ofae140","article-title":"Clinical outcomes for patients with monomicrobial vs polymicrobial Acinetobacter baumannii-calcoaceticus complex infections treated with Sulbactam-Durlobactam or Colistin: a subset analysis from a phase 3 clinical trial","volume":"11","author":"McLeod","year":"2024","journal-title":"Open. Forum. Infect. Dis."},{"issue":"14","key":"10.1016\/j.crmicr.2026.100581_bib0054","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241411752","article-title":"Induced heteroresistance in carbapenem-resistant Acinetobacter baumannii (CRAB) via exposure to Human pleural fluid (HPF) and its impact on cefiderocol susceptibility","volume":"24","author":"Mezcord","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.crmicr.2026.100581_bib0055","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01698-23","article-title":"Characterization of Acinetobacter baumannii-calcoaceticus complex isolates and microbiological outcome for patients treated with sulbactam-durlobactam in a phase 3 trial (ATTACK)","volume":"68","author":"Miller","year":"2024","journal-title":"Antimicrob. Agents Chemother"},{"issue":"10","key":"10.1016\/j.crmicr.2026.100581_bib0056","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/s41579-024-01054-w","article-title":"ESKAPE pathogens: antimicrobial resistance, epidemiology, clinical impact and therapeutics","volume":"22","author":"Miller","year":"2024","journal-title":"Nat. Rev. Microbiol."},{"issue":"8","key":"10.1016\/j.crmicr.2026.100581_bib0057","doi-asserted-by":"crossref","first-page":"5001","DOI":"10.1128\/AAC.00366-16","article-title":"Antibacterial efficacy of eravacycline in vivo against gram-positive and gram-negative organisms","volume":"60","author":"Monogue","year":"2016","journal-title":"Antimicrob. Agents Chemother"},{"issue":"3","key":"10.1016\/j.crmicr.2026.100581_bib0058","article-title":"In vitro activity of eravacycline against gram-negative Bacilli isolated in clinical laboratories worldwide from 2013 to 2017","volume":"64","author":"Morrissey","year":"2020","journal-title":"Antimicrob. Agents Chemother"},{"issue":"5","key":"10.1016\/j.crmicr.2026.100581_bib0059","doi-asserted-by":"crossref","DOI":"10.1128\/mSphere.00397-17","article-title":"A new take on an old remedy: generating antibodies against multidrug-resistant gram-negative bacteria in a postantibiotic world","volume":"2","author":"Motley","year":"2017","journal-title":"mSphere"},{"issue":"Pt B","key":"10.1016\/j.crmicr.2026.100581_bib0060","article-title":"Anti-Omp34 antibodies protect against Acinetobacter baumannii in a murine sepsis model","volume":"161","author":"Naghipour Erami","year":"2021","journal-title":"Microb. Pathog."},{"issue":"11","key":"10.1016\/j.crmicr.2026.100581_bib0061","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1093\/cid\/ciz222","article-title":"Successful treatment of antibiotic-resistant, poly-microbial bone infection with bacteriophages and antibiotics combination","volume":"69","author":"Nir-Paz","year":"2019","journal-title":"Clin. Infect. Dis."},{"issue":"1","key":"10.1016\/j.crmicr.2026.100581_bib110","article-title":"In vivo dose response and efficacy of the \u03b2-lactamase inhibitor, durlobactam, in combination with sulbactam against the Acinetobacter baumannii-calcoaceticus complex","volume":"68","author":"O\u2019Donnell","year":"2024","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.crmicr.2026.100581_bib0062","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117724","article-title":"Tissue damage alleviation and mucin inhibition by P5 in a respiratory infection mouse model with multidrug-resistant Acinetobacter baumannii","volume":"181","author":"Oh","year":"2024","journal-title":"Biomed. PharmacOther"},{"issue":"3","key":"10.1016\/j.crmicr.2026.100581_bib0063","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2024.01.012","article-title":"Cefiderocol either in monotherapy or combination versus best available therapy in the treatment of carbapenem-resistant Acinetobacter baumannii infections: a systematic review and meta-analysis","volume":"88","author":"Onorato","year":"2024","journal-title":"J. Infect."},{"issue":"5","key":"10.1016\/j.crmicr.2026.100581_bib0064","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1007\/s00134-020-05980-0","article-title":"Ventilator-associated pneumonia in adults: a narrative review","volume":"46","author":"Papazian","year":"2020","journal-title":"Intensive Care Med."},{"key":"10.1016\/j.crmicr.2026.100581_bib0065","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.66988","article-title":"A novel decoy strategy for polymyxin resistance in Acinetobacter baumannii","volume":"10","author":"Park","year":"2021","journal-title":"Elife"},{"issue":"1","key":"10.1016\/j.crmicr.2026.100581_bib0066","article-title":"Molecular and virulence characteristics of carbapenem-resistant Acinetobacter baumannii isolates: a prospective cohort study","volume":"13","author":"Park","year":"2023","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.crmicr.2026.100581_bib0067","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1128\/AAC.04808-14","article-title":"Molecular mechanisms of sulbactam antibacterial activity and resistance determinants in Acinetobacter baumannii","volume":"59","author":"Penwell","year":"2015","journal-title":"Antimicrob. Agents Chemother"},{"issue":"2","key":"10.1016\/j.crmicr.2026.100581_bib0068","doi-asserted-by":"crossref","DOI":"10.1128\/iai.00348-24","article-title":"Unveiling the role of adhesin proteins in controlling Acinetobacter baumannii infections: a systematic review","volume":"93","author":"Pereira","year":"2025","journal-title":"Infect. Immun."},{"issue":"5","key":"10.1016\/j.crmicr.2026.100581_bib0069","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1128\/AAC.00978-07","article-title":"Carbapenem-resistant Acinetobacter baumannii isolates from Tunisia producing the OXA-58-like carbapenem-hydrolyzing oxacillinase OXA-97","volume":"52","author":"Poirel","year":"2008","journal-title":"Antimicrob. Agents Chemother"},{"issue":"9","key":"10.1016\/j.crmicr.2026.100581_bib0070","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/j.1469-0691.2006.01456.x","article-title":"Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology","volume":"12","author":"Poirel","year":"2006","journal-title":"Clin. Microbiol. Infect."},{"issue":"10","key":"10.1016\/j.crmicr.2026.100581_bib0071","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00877-21","article-title":"Contribution of PER-type and NDM-type \u03b2-lactamases to cefiderocol resistance in Acinetobacter baumannii","volume":"65","author":"Poirel","year":"2021","journal-title":"Antimicrob. Agents Chemother"},{"issue":"5","key":"10.1016\/j.crmicr.2026.100581_bib0072","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.molmed.2024.02.012","article-title":"Clinical crusade: zosurabalpin's charge against antibiotic resistance","volume":"30","author":"Que","year":"2024","journal-title":"Trends Mol. Med."},{"issue":"1","key":"10.1016\/j.crmicr.2026.100581_bib0073","doi-asserted-by":"crossref","DOI":"10.1128\/msphere.00793-24","article-title":"Molecular epidemiology of carbapenem-resistant Acinetobacter baumannii group in Taiwan","volume":"10","author":"Quyen","year":"2024","journal-title":"mSphere"},{"issue":"34","key":"10.1016\/j.crmicr.2026.100581_bib0074","doi-asserted-by":"crossref","first-page":"5436","DOI":"10.1016\/j.vaccine.2020.06.052","article-title":"Type I pili, CsuA\/B and FimA induce a protective immune response against Acinetobacter baumannii","volume":"38","author":"Ramezanalizadeh","year":"2020","journal-title":"Vaccine"},{"issue":"Suppl 7","key":"10.1016\/j.crmicr.2026.100581_bib0075","doi-asserted-by":"crossref","first-page":"S538","DOI":"10.1093\/cid\/ciz826","article-title":"Cefiderocol: discovery, chemistry, and in vivo profiles of a novel siderophore cephalosporin","volume":"69","author":"Sato","year":"2019","journal-title":"Clin. Infect. Dis."},{"issue":"10","key":"10.1016\/j.crmicr.2026.100581_bib0076","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00954-17","article-title":"Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection","volume":"61","author":"Schooley","year":"2017","journal-title":"Antimicrob. Agents Chemother"},{"issue":"9","key":"10.1016\/j.crmicr.2026.100581_bib0077","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1093\/jac\/dkaa208","article-title":"In vitro activity of sulbactam\/durlobactam against global isolates of carbapenem-resistant Acinetobacter baumannii","volume":"75","author":"Seifert","year":"2020","journal-title":"J. Antimicrob. Chemother"},{"issue":"3","key":"10.1016\/j.crmicr.2026.100581_bib0078","article-title":"Phage \u03c6AB6-borne depolymerase combats Acinetobacter baumannii biofilm formation and infection","volume":"10","author":"Shahed-Al-Mahmud","year":"2021","journal-title":"Antibiotics. (Basel)"},{"key":"10.1016\/j.crmicr.2026.100581_bib0079","article-title":"Acinetobacter baumannii: an evolving and cunning opponent","volume":"15","author":"Shi","year":"2024","journal-title":"Front. Microbiol."},{"issue":"Suppl 2","key":"10.1016\/j.crmicr.2026.100581_bib0080","doi-asserted-by":"crossref","first-page":"S179","DOI":"10.1093\/cid\/ciad094","article-title":"Navigating available treatment options for carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex infections","volume":"76","author":"Shields","year":"2023","journal-title":"Clin. Infect. Dis."},{"issue":"3","key":"10.1016\/j.crmicr.2026.100581_bib0081","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s13205-022-03148-9","article-title":"Vaccine development to control the rising scourge of antibiotic-resistant Acinetobacter baumannii: a systematic review","volume":"12","author":"Singh","year":"2022","journal-title":"3. Biotech."},{"issue":"3","key":"10.1016\/j.crmicr.2026.100581_bib0082","doi-asserted-by":"crossref","first-page":"e1261","DOI":"10.1093\/cid\/ciac647","article-title":"Evolution and transmission of cefiderocol-resistant Acinetobacter baumannii during an outbreak in the burn intensive care unit","volume":"76","author":"Smoke","year":"2023","journal-title":"Clin. Infect. Dis."},{"issue":"6","key":"10.1016\/j.crmicr.2026.100581_bib0083","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1093\/cid\/ciy1029","article-title":"IGNITE4: results of a phase 3, randomized, multicenter, prospective trial of Eravacycline vs Meropenem in the treatment of complicated intraabdominal infections","volume":"69","author":"Solomkin","year":"2019","journal-title":"Clin. Infect. Dis."},{"issue":"1","key":"10.1016\/j.crmicr.2026.100581_bib0084","article-title":"Multidrug-resistant Acinetobacter baumannii: resistance mechanisms, emerging therapies, and prevention-a narrative review","volume":"15","author":"Stoian","year":"2025","journal-title":"Antibiotics. (Basel)"},{"key":"10.1016\/j.crmicr.2026.100581_bib0085","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciae403","article-title":"Infectious diseases society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections","author":"Tamma","year":"2024","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.crmicr.2026.100581_bib0086","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.900509","article-title":"Promising Acinetobacter baumannii vaccine candidates and drug targets in recent years","volume":"13","author":"Tan","year":"2022","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.crmicr.2026.100581_bib109","doi-asserted-by":"crossref","DOI":"10.3390\/v15030673","article-title":"Acinetobacter Baumannii Phages: Past, Present and Future","volume":"15","author":"Tu","year":"2023","journal-title":"Viruses"},{"issue":"8","key":"10.1016\/j.crmicr.2026.100581_bib0087","doi-asserted-by":"crossref","first-page":"e208","DOI":"10.1016\/S1473-3099(21)00612-5","article-title":"Safety and efficacy of phage therapy in difficult-to-treat infections: a systematic review","volume":"22","author":"Uyttebroek","year":"2022","journal-title":"Lancet Infect. Dis."},{"issue":"3","key":"10.1016\/j.crmicr.2026.100581_bib0088","first-page":"282","article-title":"Carbapenem resistance in Acinetobacter baumannii clinical isolates from northwest Iran: high prevalence of OXA genes in sync","volume":"13","author":"Vahhabi","year":"2021","journal-title":"Iran. J. Microbiol."},{"issue":"10","key":"10.1016\/j.crmicr.2026.100581_bib0089","doi-asserted-by":"crossref","first-page":"ofad504","DOI":"10.1093\/ofid\/ofad504","article-title":"In vivo emergence of pandrug-resistant Acinetobacter baumannii strain: comprehensive resistance characterization and compassionate use of sulbactam-durlobactam","volume":"10","author":"VanNatta","year":"2023","journal-title":"Open Forum. Infect. Dis."},{"issue":"2","key":"10.1016\/j.crmicr.2026.100581_bib0090","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1128\/CMR.18.2.306-325.2005","article-title":"Metallo-beta-lactamases: the quiet before the storm?","volume":"18","author":"Walsh","year":"2005","journal-title":"Clin. Microbiol. Rev."},{"issue":"1","key":"10.1016\/j.crmicr.2026.100581_bib0091","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.scib.2024.08.004","article-title":"Zosurabalpin like petrichor: a novel antibiotic class with unprecedented target towards Acinetobacter baumannii","volume":"70","author":"Wen","year":"2024","journal-title":"Sci. Bull."},{"issue":"8","key":"10.1016\/j.crmicr.2026.100581_bib0092","doi-asserted-by":"crossref","first-page":"e696","DOI":"10.1002\/mco2.696","article-title":"Zosurabalpin: a novel tethered macrocyclic peptide antibiotic that kills carbapenem-resistant Acinetobacter baumannii","volume":"5","author":"Weng","year":"2024","journal-title":"MedComm"},{"issue":"1","key":"10.1016\/j.crmicr.2026.100581_bib0093","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1038\/s41598-022-06582-0","article-title":"Enhanced antibacterial effect of a novel friunavirus phage vWU2001 in combination with colistin against carbapenem-resistant Acinetobacter baumannii","volume":"12","author":"Wintachai","year":"2022","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.crmicr.2026.100581_bib0094","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1080\/22221751.2021.1902754","article-title":"Pre-optimized phage therapy on secondary Acinetobacter baumannii infection in four critical COVID-19 patients","volume":"10","author":"Wu","year":"2021","journal-title":"Emerg. Microbes. Infect."},{"issue":"2","key":"10.1016\/j.crmicr.2026.100581_bib0095","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1473-3099(20)30731-3","article-title":"Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial","volume":"21","author":"Wunderink","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.crmicr.2026.100581_bib0096","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2020.589253","article-title":"First report of New Delhi metallo-\u03b2-lactamase-6 (NDM-6) in a clinical Acinetobacter baumannii isolate from Northern Spain","volume":"11","author":"Xanthopoulou","year":"2020","journal-title":"Front. Microbiol."},{"issue":"7","key":"10.1016\/j.crmicr.2026.100581_bib0097","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s10096-020-04121-1","article-title":"Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: narrative review","volume":"41","author":"Yaghoubi","year":"2021","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"issue":"4","key":"10.1016\/j.crmicr.2026.100581_bib0098","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2024.107106","article-title":"Antimicrobial peptide DvAMP combats carbapenem-resistant Acinetobacter baumannii infection","volume":"63","author":"Yang","year":"2024","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.crmicr.2026.100581_bib0099","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1088130","article-title":"Subunit vaccines for Acinetobacter baumannii","volume":"13","author":"Yang","year":"2023","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.crmicr.2026.100581_bib0100","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202408292","article-title":"OMP38 of carbapenem-resistant Acinetobacter Baumannii-mediated mtDNA release activates the cGAS-STING signaling to induce inflammatory response","volume":"12","author":"Yang","year":"2024","journal-title":"Adv. Sci."},{"issue":"1","key":"10.1016\/j.crmicr.2026.100581_bib0101","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12941-020-00411-w","article-title":"First detection of a plasmid-encoded New-Delhi metallo-beta-lactamase-1 (NDM-1) producing Acinetobacter baumannii using whole genome sequencing, isolated in a clinical setting in Benin","volume":"20","author":"Yehouenou","year":"2021","journal-title":"Ann. Clin. Microbiol. Antimicrob."},{"key":"10.1016\/j.crmicr.2026.100581_bib0103","doi-asserted-by":"crossref","first-page":"76","DOI":"10.3389\/fimmu.2020.00076","article-title":"Monoclonal IgM antibodies targeting Candida albicans Hyr1 provide cross-Kingdom protection against gram-negative bacteria","volume":"11","author":"Youssef","year":"2020","journal-title":"Front. Immunol."},{"issue":"7995","key":"10.1016\/j.crmicr.2026.100581_bib0102","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/s41586-023-06873-0","article-title":"A novel antibiotic class targeting the lipopolysaccharide transporter","volume":"625","author":"Zampaloni","year":"2024","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.crmicr.2026.100581_bib0104","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s40265-016-0545-8","article-title":"Review of Eravacycline, a novel fluorocycline antibacterial agent","volume":"76","author":"Zhanel","year":"2016","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.crmicr.2026.100581_bib0105","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s40265-019-1055-2","article-title":"Cefiderocol: a siderophore cephalosporin with activity against carbapenem-resistant and multidrug-resistant gram-negative Bacilli","volume":"79","author":"Zhanel","year":"2019","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.crmicr.2026.100581_bib0106","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1186\/s12866-025-04283-y","article-title":"High-throughput single-cell analysis reveals fully human Omp38-specific monoclonal antibodies against Acinetobacter baumannii","volume":"25","author":"Zhang","year":"2025","journal-title":"BMC Microbiol."},{"issue":"1","key":"10.1016\/j.crmicr.2026.100581_bib0107","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1186\/s12879-019-4093-1","article-title":"In vitro activities of Eravacycline against 336 isolates collected from 2012 to 2016 from 11 teaching hospitals in China","volume":"19","author":"Zhao","year":"2019","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.crmicr.2026.100581_bib0108","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.jgar.2025.06.021","article-title":"Comparative in vitro activities of eravacycline and tigecycline against carbapenem-resistant Acinetobacter baumannii: insights from whole genome sequencing analysis","volume":"44","author":"Zhong","year":"2025","journal-title":"J. Glob. Antimicrob. Resist."}],"container-title":["Current Research in Microbial Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666517426000362?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666517426000362?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T15:38:42Z","timestamp":1788277122000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666517426000362"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":109,"alternative-id":["S2666517426000362"],"URL":"https:\/\/doi.org\/10.1016\/j.crmicr.2026.100581","relation":{},"ISSN":["2666-5174"],"issn-type":[{"value":"2666-5174","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic challenges and emerging strategies against carbapenem-resistant Acinetobacter baumannii","name":"articletitle","label":"Article Title"},{"value":"Current Research in Microbial Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.crmicr.2026.100581","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100581"}}